NRSN

Neurosense Therapeutics Ltd

NRSN, USA

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

https://www.neurosense-tx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NRSN
stock
NRSN

$NRSN Q3 2025 Earnings Preview: Recent $NRSN Insider Trading, Hedge Fund Activity, and More Quiver Quantitative

Read more →
NRSN
stock
NRSN

Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

Target Price:

$11.5

Analyst Picks

Strong Buy

2

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-43.56

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

453.66 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-139.82 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 1.75% of the total shares of Neurosense Therapeutics Ltd

1.

Citadel Advisors Llc

(0.5959%)

since

2025/06/30

2.

Morgan Stanley - Brokerage Accounts

(0.319%)

since

2025/06/30

3.

Squarepoint Ops LLC

(0.1994%)

since

2025/06/30

4.

Meitav Dash Investments Ltd

(0.1597%)

since

2025/06/30

5.

Jane Street Group LLC

(0.1146%)

since

2025/06/30

6.

HRT FINANCIAL LLC

(0.0866%)

since

2025/06/30

7.

Commonwealth Equity Services Inc

(0.0842%)

since

2025/06/30

8.

Geode Capital Management, LLC

(0.0634%)

since

2025/06/30

9.

Fidelity Nasdaq Composite Index

(0.0634%)

since

2025/07/31

10.

BNP Paribas Arbitrage, SA

(0.0272%)

since

2025/06/30

11.

Hurley Capital, LLC

(0.0261%)

since

2025/06/30

12.

UBS Group AG

(0.0064%)

since

2025/06/30

13.

CWM, LLC duplicate

(0.004%)

since

2025/06/30

14.

Total Investment Management Inc

(0.002%)

since

2025/06/30

15.

Warberg Asset Management LLC

(0%)

since

2025/06/30

16.

Stratos Wealth Partners, LTD

(0%)

since

2025/03/31

17.

XTX Topco Ltd

(0%)

since

2025/06/30

18.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.0458

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

-0.055

EPS Difference

0.055

Surprise Percent

100%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.